Literature DB >> 28232309

Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.

Masayuki Nigo1, Lorena Diaz2,3, Lina P Carvajal2, Truc T Tran1,3, Rafael Rios2, Diana Panesso1,2,3, Juan D Garavito2, William R Miller1,3, Audrey Wanger4, George Weinstock5, Jose M Munita1,2,3,6, Cesar A Arias7,2,3, Henry F Chambers8.   

Abstract

We report a case of infective endocarditis (IE) caused by ceftaroline-resistant, daptomycin-tolerant, and heterogeneous vancomycin-intermediate methicillin-resistant S. aureus (MRSA). Resistance to ceftaroline emerged in the absence of drug exposure, and the E447K substitution in the active site of PBP2a previously associated with ceftaroline resistance was identified. Additionally, we present evidence of patient-to-patient transmission of the strain within the same unit. This case illustrates the difficulties in treating MRSA IE in the setting of a multidrug-resistant phenotype.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus aureus; ceftaroline; endocarditis

Mesh：

Substances：

Year:  2017        PMID： 28232309      PMCID： PMC5328541          DOI： 10.1128/AAC.01235-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

1.  Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.

Authors:  Yoshio Takesue; Kazuhiko Nakajima; Yoshiko Takahashi; Kaori Ichiki; Mika Ishihara; Yasunao Wada; Toshie Tsuchida; Motoi Uchino; Hiroki Ikeuchi
Journal:  J Infect Chemother       Date:  2010-07-13       Impact factor: 2.211

Review 2.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Authors:  S J van Hal; T P Lodise; D L Paterson
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

3.  Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Shey-Ying Chen; Chun-Hsing Liao; Jiun-Ling Wang; Wen-Chu Chiang; Mei-Shu Lai; Wei-Chu Chie; Shan-Chwen Chang; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2013-08-29       Impact factor: 5.790

4.  Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.

Authors:  James Price; Stephen Atkinson; Martin Llewelyn; John Paul
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

5.  Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Authors:  Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

6.  Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.

Authors:  Peter G Kelley; Wei Gao; Peter B Ward; Benjamin P Howden
Journal:  J Antimicrob Chemother       Date:  2011-03-02       Impact factor: 5.790

7.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

8.  Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

9.  Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": Taking advantage of the back door left open?

Authors:  Jessica K Ortwine; Brian J Werth; George Sakoulas; Michael J Rybak
Journal:  Drug Resist Updat       Date:  2013-10-25       Impact factor: 18.500

10.  Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.

Authors:  Warren E Rose; Lucas T Schulz; David Andes; Rob Striker; Andrew D Berti; Paul R Hutson; Sanjay K Shukla
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191
View more
  7 in total

1.  Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.

Authors:  Betsy E Castro; Maritza Berrio; Monica L Vargas; Lina P Carvajal; Lina V Millan; Rafael Rios; Angie K Hernandez; Sandra Rincon; Paola Cubides; Erika Forero; An Dinh; Carlos Seas; Jose M Munita; Cesar A Arias; Jinnethe Reyes; Lorena Diaz
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

Review 2.  The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Kyle C Molina; Taylor Morrisette; Matthew A Miller; Vanthida Huang; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Nicolas Cortes-Penfield; Nora T Oliver; Andrew Hunter; Maria Rodriguez-Barradas
Journal:  Infect Dis (Lond)       Date:  2018-03-06

4.  Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.

Authors:  J Chase McNeil; Lauren M Sommer; Jesus G Vallejo; Kristina G Hulten; Sheldon L Kaplan; Anthony R Flores
Journal:  Antimicrob Agents Chemother       Date:  2022-09-27       Impact factor: 5.938

5.  Are Antimicrobial Peptide Dendrimers an Escape from ESKAPE?

Authors:  Yayoi Kawano; Olivier Jordan; Takehisa Hanawa; Gerrit Borchard; Viorica Patrulea
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-05-19       Impact factor: 4.730

6.  Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure.

Authors:  Joseph Patrik Hornak; Seher Anjum; David Reynoso
Journal:  Ther Adv Infect Dis       Date:  2019-11-07

7.  Systematic optimization for production of the anti-MRSA antibiotics WAP-8294A in an engineered strain of Lysobacter enzymogenes.

Authors:  Xusheng Chen; Shanren Li; Lingjun Yu; Amanda Miller; Liangcheng Du
Journal:  Microb Biotechnol       Date:  2019-09-14       Impact factor: 5.813
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.